Newsroom
Sorted by: Latest
-
agilon health Reports ACO REACH Model Results for 2024 Performance Year
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, announced that its Accountable Care Organizations (ACOs) achieved $229 million in gross savings (13.6% gross savings rate), including $54 million savings in the Medicare Trust Fund, during the 2024 performance year of the ACO Realizing Equity, Access and Community Health (ACO REACH) model. agilon’s eight REACH ACOs operate under full risk, a...
-
Causeway Capital Management LLC UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Causeway Capital Management LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must b...
-
National Life Group Named to 2026 Ward’s 50 Top Performing Life and Health Insurance Companies
MONTPELIER, Vt.--(BUSINESS WIRE)--National Life Group has been named to the 2026 Ward’s 50 Top Performing Insurance Companies, an annual list of the country’s 50 top performing life and health insurance companies. According to Ward’s, National Life Group was selected out of nearly 700 life and health insurance organizations based on its outstanding financial results in the areas of safety, consistency, and performance over a five-year period (2021-2025). 2026 marks the sixth consecutive year in...
-
Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced Michael McFadden, Chief Executive Officer, will participate in the Late-Stage & Commercial CNS Small Cap panel discussion during the upcoming B. Riley Securities Mind, Muscle & Vision Summit, taking place July 16th in Boston, Massachu...
-
Hyliion to Showcase KARNO Technology at 2026 Pennsylvania Defense and Innovation Summit
AUSTIN, Texas--(BUSINESS WIRE)--Hyliion Holdings Corp. (NYSE American: HYLN), a developer of modular power plant technology, today announced that Hyliion will showcase the KARNO technology and participate in the 2026 Pennsylvania Defense and Innovation Summit at the U.S. Army War College on July 14 and 15. Thomas Healy, Founder and Chief Executive Officer of Hyliion will join this invitation-only gathering hosted by Senator Dave McCormick (R-PA). Remarks at the summit are expected from Presiden...
-
DEWA International debiutuje jako samodzielna jednostka zależna będąca w całości własnością DEWA, która realizować będzie globalne projekty z zakresu energii i gospodarki wodnej
DUBAJ, Zjednoczone Emiraty Arabskie--(BUSINESS WIRE)--Jego Wysokość szejk Ahmed bin Saeed Al Maktum, prezes Najwyższej Rady Energetycznej w Dubaju, przekazał informację o utworzeniu podmiotu „DEWA International”, samodzielnej spółki zależnej będącej w całości własnością Urzędu ds. Energii Elektrycznej i Wody w Dubaju (DEWA). Spółka ma realizować konwencjonalne projekty energetyczne oraz projekty w zakresie energii odnawialnej na całym świecie i przenieść skuteczny model infrastruktury energetyc...
-
Precisio Biotix Therapeutics, Inc. (Precisio) Announces the Use of Its ClyO (Staph Lysin) to Treat a Multi Drug-Resistant Prosthetic Joint Infection (PJI) Under an Expanded Access Chronic Care Management Protocol
DOVER, Del.--(BUSINESS WIRE)--Precisio announced the continuation of its expanded access program, with dosing of a staph lysin called ClyO (LYSG101) to a patient with chronic prosthetic joint infection. Under an FDA-approved expanded-access IND, administration of ClyO was initiated on June 1. The treatment follows a 4 month protocol with a minimum 6 month follow-up. Outcomes to be tracked include safety, improvements of clinical signs and symptoms, and either durable eradication or sustained sup...
-
Mirion Supports Advanced Reactor Criticality Milestones Through U.S. DOE Reactor Pilot Program
ATLANTA--(BUSINESS WIRE)--Mirion, a global leader in radiation safety, science, and medicine, announced today that its Mirion Technologies and Paragon Energy Solutions businesses supported multiple advanced reactor designs that have achieved criticality milestones in the U.S. Department of Energy (DOE) Reactor Pilot Program, established under Executive Order 14301. In May 2025, the Administration issued executive orders to strengthen and accelerate the U.S. nuclear industry. Executive Order 143...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF 10% - January 09.07.2026 FJAN.LN IE000MDKBOB3 150,002.00 USD 4,344,318.67 28.962 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Nasdaq Clean Edge Global Water UCITS ETF 09.07.2026 H2O LN IE000Q8F0M81 600,002.00 USD 12,107,386.27 20.179 ...